Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer

Critical Reviews in Oncology/Hematology

Volumn 97, Issue , 2016, Pages 85-95

  Mirone, Giovanna ^a   Shukla, Arvind ^b   Marfe, Gabriella ^c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b D Y PATIL UNIVERSITY   (India)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Colorectal cancer; Epidermal Growth Factor Receptor; Gefitinib; Vascular Endothelial Growth Factor VEGF 1

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REGORAFENIB; VASCULOTROPIN; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84952636691     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.08.012     Document Type: Review

References (144)

1. Achen M.G., Stacker S.A. The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int. J. Exp. Pathol. 1998, 79:255-265.
2. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
3. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in non human cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 2001, 19(Suppl. 18):32S-40S.
4. Ayers M., Awad M., Malone D. Association of K-ras status with efficacy end points from a phase 1/2 study of brivanib in combination with cetuximab in patients with advanced or metastatic colorectal cancer (CRC). American Society of Clinical Oncology Gastrointestinal Cancers (ASCO-GI) Symposium 2009, Abstract 375.
5. Baba Y., Nosho K., Shima K., Hayashi M., Meyerhardt J.A., Chan A.T., Giovannucci E., Fuchs C.S., Ogino S.P., hosphorylated A.K.T. Expression is associated with PIK3CA mutation, low stage and favorable outcome in 717 colorectal cancers. Cancer 2011, 117:1399-1408.
6. Bajetta E., Di Bartolomeo M., Buzzoni R., Ferrario E., Dotti K.F., Mariani L., Bajetta R., Gevorgyan A., Venturino P., Galassi M. Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer Chemother. Pharmacol. 2009, 64:67-72.
7. Barault L., Veyrie N., Jooste V., Lecorre D., Chapusot C., Ferraz J.M., Lièvre A., Cortet M., Bouvier A.M., Rat P., Roignot P., Faivre J., Laurent-Puig P., Piard F. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 2008, 122:2255-2259.
8. Barber T.D., Vogelstein B., Kinzler K.W., Velculescu V.E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 2004, 351:2883.
9. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
10. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Corà D., Di Nicolantonio F., Buscarino M., Petti C., Ribero D., Russolillo N., Muratore A., Massucco P., Pisacane A., Molinaro L., Valtorta E., Sartore-Bianchi A., Risio M., Capussotti L., Gambacorta M., Siena S., Medico E., Sapino A., Marsoni S., Comoglio P.M., Bardelli A., Trusolino L. A molecularly annotated platform of patient derived xenografts (xenopatients) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal, cancer. Cancer Discov. 2011, 1:508-523.
11. Blaszkowsky L.S., Ryan D.P., Szymonifka J., Borger D.R., Zhu A.X., Clark J.W., Kwak E.L., Mamon H.J., Allen J.N., Vasudev E., Shellito P.C., Cusack J.C., Berger D.L., Hong T.S. Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann. Oncol. 2014, 25:121-126.
12. Bokemeyer C., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:663-667.
13. Bokemeyer C., Bondarenko I., Hartmann J.T., de Braud F., Schuch G., Zubel A., Celik I., Schlichting M., Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 2011, 22:1535-1546.
14. Camirand A., Zakikhani M., Young F., Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res. 2005, 7:R570-579.
15. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.H., Claesson-Welsh L., Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A 1998, 95:14389-14394.
16. Carlomagno C., Daniele G., Bianco R., Marciano R., Damiano V., Matano E., Nappi L., Pepe S., De Placido S., Tortora G. Addition of erlotinib to fluoropyrimidine-oxaliplatin based chemotherapy with or without bevacizumab: two sequential phase I trials. Exp. Ther. Med. 2011, 2:449-455.
17. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
18. Castellarin M., Warren R.L., Freeman J.D., Dreolini L., Krzywinski M., Strauss J., Barnes R., Watson P., Allen-Vercoe E., Moore R.A., Holt R.A. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012, 22:299-306.
19. Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann. Oncol. 2010, 21(Suppl 2):v93-v97.
20. Chau I., Cunningham D., Hickish T., Massey A., Higgins L., Osborne R., Botwood N., Swaisland A. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann. Oncol. 2007, 18:730-737.
21. Cho I., Blaser M.J. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 2012, 13:260-270.
22. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23:1803-1810.
23. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358:1160-1174.
24. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., Fan Z., Mendelsohn J., Bianco A.R., Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 1999, 5:909-916.
25. Ciardiello F., Normanno N., Maiello E.M., Martinelli E., Troiani T., Pisconti S., Giuliani F., Barone C., Cartenì G., Rachiglio A.M., Montesarchio V., Tonini G., Rizzi D., Cinieri S., Bordonaro R., Febbraro A., De V., ita F., Orditura M., Fenizia F., Lambiase M., Rinaldi A., Tatangelo F., Botti G., Colucci G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann. Oncol. 2014, 25:1756-1761.
26. Clinicaltrials. gov. Cetuximab with or without brivanib in treating patients with metastatic colorectal cancer http://clinicaltrials.gov/ ct2/ (accessed 30.11.10.).
27. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van C., Van Custsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
28. Dahabreh I.J., Terasawa T., Castaldi P.J., Trikalinos T.A. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann. Int. Med. 2011, 154:37-49.
29. Day F.L., Jorissen R.N., Lipton L., Mouradov D., Sakthianandeswaren A., Christie M., Li S., Tsui C., Tie J., Desai J., Xu Z.Z., Molloy P., Whitehall V., Leggett B.A., Jones I.T., McLaughlin S., Ward R.L., Hawkins N.J., Ruszkiewicz A.R., Moore J., Busam D., Zhao Q., Strausberg R.L., Gibbs P., Sieber O.M. PIK3CA and PTEN gene and exon mutation-specific clinicopathological and molecular associations in colorectal cancer. Clin. Cancer Res. 2013, 9:3285-3296.
30. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
31. De Roock J., Jonker D.J., Nicolantonio F., Sartore-Bianchi A., Tu D., Siena S., Lamba S., Arena S., Frattini M., Piessevaux H., Van Cutsem E., O'Callaghan C.J., Khambata-Ford S., Zalcberg J.R., Simes J., Karapetis C.S., Bardelli A., Tejpar S. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
32. De Mattia E., Cecchin E., Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist. Updat. 2015, pii: S1368-7646(15)00024-2.
33. Demetri G.D., Reichardt P., Kang Y.K., Blay J.Y., Rutkowski P., Gelderblom H., Hohenberger P., Leahy M., von Mehren M., Joensuu H., Badalamenti G., Blackstein M., Le C., esne A., Schöffski P., Maki R.G., Bauer S., Nguyen B.B., Xu J., Nishida T., Chung J., Kappeler C., Kuss I., Laurent D., Casali P.G., GRID, study investigators Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:295-302.
34. Desbois-Mouthon C., Baron A., Blivet-Van Eggelpoël M.J., Fartoux L., Venot C., Bladt F., Housset C., Rosmorduc O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:5445-5456.
35. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:5705-5712.
36. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., Rivera F., Kocákova I., Ruff P., Błasińska-Morawiec M., Šmakal M., Canon J.L., Rother M., Oliner K.S., Wolf M., Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010, 28:4697-4705.
37. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., Ince W.L., Jänne P.A., Januario T., Johnson D.H., Klein P., Miller V.A., Ostland M.A., Ramies D.A., Sebisanovic D., Stinson J.A., Zhang Y.R., Seshagiri S., Hillan K.J. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 2005, 23:5900-5909.
38. Economopoulou E., Kotsakis A., Kapiris I., Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag. Res. 2015, 15:133-143.
39. Edelman M.J., Mao L. Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences. Transl. Lung Cancer Res. 2013, 2:304-307.
40. Edkins S., O'Meara S., Parker A., Stevens C., Reis M., Jones S., Greenman C., Davies H., Dalgliesh G., Forbes S., Hunter C., Smith R., Stephens P., Goldstraw P., Nicholson A., Chan T.L., Velculescu V.E., Yuen S.T., Leung S.Y., Stratton M.R., Futreal P.A. Recurrent K.R.A.S. codon 146 mutations in human colorectal cancer. Cancer Biol. Ther. 2006, 5:928-932.
41. Eklof V., Wikberg M.L., Edin S., Dahlin Å.M., Jonsson B.Å., Öberg Å., Rutegård J., Palmqvist R. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br. J. Cancer 2013, 108:2153-2163.
42. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of antitumour activity. Nat. Rev. Cancer. 2008, 8:579-591.
43. Elsabah M.T., Adel I. Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J. Egypt Natl. Cancer Inst. 2013, 25:51-56.
44. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
45. Falchook G.S., Naing A., Wheler J.J., Tsimberidou A.M., Zinner R., Hong D.S., Fu S., Piha-Paul S.A., Janku F., Hess K.R., Bastida C., Kurzrock R., Dual E.G.F.R. inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 2014, 1:540-549.
46. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
47. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. 2012, 12:298-306.
48. Garrett C.R., Siu L.L., El-Khoueiry A., Buter J., Rocha-Lima C.M., Marshall J., LoRusso P., Major P., Chemidlin J., Mokliatchouk O., Velasquez L., Hayes W., Feltquate D., Syed S., Ford S., Kollia G., Galbraith S., Nuyten D.S. Phase I. dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br. J. Cancer. 2011, 105:44-52.
49. Gatenby R.A., Silva A.S., Gillies R.J., Frieden B.R. Adaptive therapy. Cancer Res. 2009, 69:4894-4903.
50. Gavin P., Colangelo L.H., Fumagalli D., Tanaka N., Remillard M.Y., Yothers G., Kim C., Taniyama Y., Kim S.I., Choi H.J., Blackmon N.L., Lipchik C., Petrelli N.J., O'Connell M.J., Wolmark N., Paik S., Pogue-Geile K.L. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin. Cancer Res. 2012, 18:6531-6541.
51. Gomez-Manzano C., Holash J., Fueyo J., Xu J., Conrad C.A., Aldape K.D., de G., root J.F., Bekele B.N., Yung W.K. VEGF trap induces antiglioma effect at different stages of disease. Neuro. Oncol. 2008, 10:940-945.
52. Grady W.M., Markowitz S.D. The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig. Dis. Sci. 2015, 60:762-772.
53. Gridelli C., Bareschino M.A., Schettino C., Rossi A., Maione P., Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007, 12:840-849.
54. Grothey A., Hedrick E.E., Mass R.D., Sarkar S., Suzuki S., Ramanathan R.K., Hurwitz H.I., Goldberg R.M., Sargent D.J. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J. Clin. Oncol. 2008, 26:183-189.
55. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., Humblet Y., Bouché O., Mineur L., Barone C., Adenis A., Tabernero J., Yoshino T., Lenz H.J., Goldberg R.M., Sargent D.J., Cihon F., Cupit L., Wagner A., Laurent D., CORRECTS, tudy G., roup Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013, 381:303-312.
56. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., Engelman J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118:2609-2619.
57. Hanauske A.R., Cassidy J., Sastre J., Bolling C., Jones R.J., Rakhit A., Fettner S., Brennscheidt U., Feyereislova A., Díaz-Rubio E. Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clin. Cancer Res. 2007, 13:523-531.
58. Hocking C.M., Price T.J. Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therap. Adv. Gastroenterol 2014, 7:20-37.
59. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., Rudge J.S. VEGF-trap. a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11393-11398.
60. Holden D.J., Jonas D.E., Porterfield D.S., Reuland D., Harris R. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann. Intern. Med. 2010, 152:668-676.
61. Hong Y.S., Nam B.H., Kim K.P., Kim J.E., Park S.J., Park Y.S., Park J.O., Kim S.Y., Kim T.Y., Kim J.H., Ahn J.B., Lim S.B., Yu C.S., Kim J.C., Yun S.H., Kim J.H., Park J.H., Park H.C., Jung K.H., Kim T.W. Oxaliplatin, fluorouracil,and leucovorin versus fluorouracil and leucovorin as adjuvantchemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014, 15:1245-1253.
62. Jain, R., Duda, D., Sorensen, A., 2009. Emerging paradigms and potential biomarkers of response and resistance in antiangiogenic Therap. Cancer, in ASCO Educational Manuscript. 6.
63. Janku F., Lee J.J., Tsimberidou A.M., Hong D.S., Naing A., Falchook G.S., Fu S., Luthra R., Garrido-Laguna I., Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011, 6:e22769.
64. Jia Y., Liu M., Huang W., Wang Z., He Y., Wu J., Ren S., Ju Y., Geng R., Li Z. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol. Oncol. Res. 2012, 18:315-323.
65. Jitawatanarat P., Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J. Gastrointest Oncol. 2013, 4:231-238.
66. Jones H.E., Goddard L., Gee J.M., Hiscox S., Rubini M., Barrow D., Knowlden J.M., Williams S., Wakeling A.E., Nicholson R.I. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer 2004, 11:793-814.
67. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., Berry S.R., Krahn M., Price T., Simes R.J., Tebbutt N.C., van H., azel G., Wierzbicki R., Langer C., Moore M.J. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357:2040-2048.
68. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
69. Kim E.S., Serur A., Huang J., Manley C.A., McCrudden K.W., Frischer J.S., Soffer S.Z., Ring L., New T., Zabski S., Rudge J.S., Holash J., Yancopoulos G.D., Kandel J.J., Yamashiro D.J. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11399-11404.
70. Kohne C., Stroiakovski D., Chang-Chien C., Lim R., Pintér T., Bodoky G., Stroh C., Celik I., Rougier P., Van Cutsem E.E., Oldenburg K. Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial (abstr 4068). J. Clin. Oncol. 2009, 27(Suppl).
71. Kostic A.D., Gevers D., Pedamallu C.S., Michaud M., Duke F., Earl A.M., Ojesina A.I., Jung J., Bass A.J., Tabernero J., Baselga J., Liu C., Shivdasani R.A., Ogino S., Birren B.W., Huttenhower C., Garrett W.S., Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012, 22:292-298.
72. Landry J.C., Feng Y., Prabhu R.S., Cohen S.J., Staley C.A., Whittington R., Sigurdson E.R., Nimeiri H., Verma U., Benson A.B. Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin(FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN. Cancer 2015, 106-2015. Research Group E3204. Oncologist. Apr 29. pii: theoncologist.
73. Lee J.J., Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin. Colorectal Cancer 2014, 13:135-144.
74. Lee, C.K., Wu, Y.L., Ding, P.N., Lord, S.J., Inoue, A., Zhou, C., Mitsudomi, T.R., Rosell, Pavlakis, N., Links, M., Gralla, R.J., Yang, J.C.H., 2015. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisEpidermal growth factor receptor mutations in lung Adenocarcinoma CO JCO. 2014.58.1736; published online on April 20.
75. Li J., Qin S., Xu R., Yau T.C., Ma B., Pan H., Xu J., Bai Y., Chi Y., Wang L., Yeh K.H., Bi F., Cheng Y., Le A.T., Lin J.K., Liu T., Ma D., Kappeler C., Kalmus J., Kim T.W. CONCUR Investigators. Regorafenib plus best supportive care versus placeboplus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015, Published online May 14 pii: S1470(15)70156-7.
76. Lièvre A., Bachet J.B., Boige V., Cayre A., Le, Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
77. Liao X., Lochhead P., Nishihara R., Kuchiba A., Yamauchi M., Imamura Y., Qian Z.R., Baba Y., Shima K., Sun R., Nosho K., Meyerhardt J.A., Giovannucci E., Fuchs C.S., Chan A.T., Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 2012, 367:1596-1606.
78. Liao X., Morikawa T., Lochhead P., Imamura Y., Kuchiba A., Yamauchi M., Nosho K., Qian Z.R., Nishihara R., Meyerhardt J.A., Fuchs C.S., Ogino S. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin. Cancer Res. 2012, 18:2257-2268.
79. Luo H.Y., Xu R.H. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J. Gastroenterol 2014, 20:3858-3874.
80. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361:2449-2460.
81. Mc Kay J.A., Murray L.J., Curran S., Ross V.G., Clark C., Murray G.I., Cassidy J., McLeod H.L. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastases. Eur. J. Cancer 2002, 38:2258-2264.
82. Metzger B., Chambeau L., Begon D.Y., Faber C., Kayser J., Berchem G., Pauly M., Boniver J., Delvenne P., Dicato M., Wenner T. The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med. Genet. 2011, 12:144.
83. Meyerhardt J.A., Stuart K., Fuchs C.S., Zhu A.X., Earle C.C., Bhargava P., Blaszkowsky L., Enzinger P., Mayer R.J., Battu S., Lawrence C., Ryan D.P. Phase I.I. study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann. Oncol. 2007, 18:1185-1189.
84. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005, 23:2513-2520.
85. Morgillo F., Cantile F., Fasano M., Troiani T., Martinelli E., Ciardiello F. Resistance mechanisms of tumor cells to EGFR inhibitors. Clin. Transl. Oncol. 2009, 11:270-275.
86. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6:279-286.
87. Muñoz A., Pericay C., García-Girón C., Alonso V., Dueñas R., Cirera L., Rivera F., Falcó E., Bustos I.A., Salud A.P. Phase I.I. study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. Oncol. Res. 2013, 21:181-191.
88. Nagahara H., Mimori K., Ohta M., Utsunomiya T., Inoue H., Barnard G.F., Ohira M., Hirakawa K., Mori M. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin. Cancer Res. 2005, 11:1368-1371.
89. Napolitano S., Martini G., Rinaldi B., Martinelli E., Donniacuo M., Berrino L., Vitagliano D., Morgillo F., Barra G., De Palma R., Merolla F., Ciardiello F., Troiani T. Primary and acquired resistance of colorectal cancer to antiEGFR monoclonal antibody can be overcome by combined treatment of regorafenib with cetuximab. Clin. Cancer Res. 2015, April.
90. Niault T.S., Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010, 31:1165-1174.
91. Normanno N., Rachiglio A.M., Lambiase M., Martinelli E., Fenizia F., Esposito C., Roma C., Troiani T., Rizzi D., Tatangelo F., Botti G., Maiello E., Colucci G., Ciardiello F. On the behalf of the CAPRIGOIM investigators. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potentialeffects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015, Apr 7. pii : mdv1769.
92. Ogino S., Chan A.T., Fuchs C.S., Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011, 60:397-411.
93. Ogino S., Shima K., Meyerhardt J.A., McCleary N.J., Ng K., Hollis D., Saltz L.B., Mayer R.J., Schaefer P., Whittom R., Hantel A., Benson 3 A.B., rd S., piegelman D., Goldberg R.M., Bertagnolli M.M., Fuchs C.S. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89,803. Clin. Cancer Res. 2012, 18:890-900.
94. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
95. Phipps A.I., Makar K.W., Newcomb P.A. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int. J. Colorectal Dis. 2013, 28:1637-1642.
96. Prager G.W., Poettler M., Unseld M., Zielinski C.C. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl. Lung Cancer Res. 2012, 1:14-25.
97. Prenen H., De S., chutter J., Jacobs B., De R., oock W., Biesmans B., Claes B., Lambrechts D., Van Cutsem E., Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. cancer res. 2009, 15:3184-3188.
98. Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60:116-129.
99. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Tumorigenesis Velculescu V.E. RAF/RAS oncogenes and mismatchrepair status. Nature. 2002, 418:934.
100. Riechelmann R., Grothey A. The role of regorafenib in metastatic colorectal cancer. Lancet Oncol. 2015, (May 13). pii: S1470-2045(15)70191-9.
101. Roberts R.B., Min L., Washington M.K., Olsen S.J., Settle S.H., Coffey R.J., Threadgill D.W. Importance of epidermal growth factor receptor signaling in establishment of adenomas maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1521-1526.
102. Rosa R., Marciano R., Malapelle U., Formisano L., Nappi L., D'Amato C., D'Amato V., Damiano V., Marfè G., Del Vecchio S., Zannetti A., Greco A., De Stefano A., Carlomagno C., Veneziani B.M., Troncone G., De Placido S., Bianco R. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin. Cancer Res. 2013, 19:138-147.
103. Rosty C., Young J.P., Walsh M.D., Clendenning M., Sanderson K., Walters R.J., Parry S., Jenkins M.A., Win A.K., Southey M.C., Hopper J.L., Giles G.G., Williamson E.J., English D.R., Buchanan D.D. PIK3CA. activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One 2013, 8(6):e65479.
104. Ruckhäberle E., Rody A., Engels K., Gaetje R., von Minckwitz G., Schiffmann S., Grösch S., Geisslinger G., Holtrich U., Karn T., Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat. 2008, 112:41-52.
105. Rudge J.S., Holash J., Hylton D., Russell M., Jiang S., Leidich R., Papadopoulos N., Pyles E.A., Torri A., Wiegand S.J., Thurston G., Stahl N., Yancopoulos G.D. Inaugural article: VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18363-18370.
106. Sakurada A., Shepherd F.A., Tsao M.S. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin. Lung Cancer 2006, 7(Suppl. 4):S138-S144.
107. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase I.I. trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22:1201-1208.
108. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304-554.
109. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22:2954-2963.
110. Sartore-Bianchi A., Moroni M., Veronese S., Carnaghi C., Bajetta E., Luppi G., Sobrero A., Barone C., Cascinu S., Colucci G., Cortesi E., Nichelatti M., Gambacorta M., Siena S. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 2007, 25:3238-3245.
111. Sartore-Bianchi A., Bencardino K., Di Nicolantonio F., Pozzi F., Funaioli C., Gambi V., Arena S., Martini M., Lamba S., Cassingena A., Schiavo R., Bardelli A., Siena S. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol. 2010, 5:19-28.
112. Schutz F.A., Je Y., Azzi G.R., Nguyen P.L., Choueiri T.K. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focuson different subgroup outcomes. Ann Oncol. 2011, 22:1404-1412.
113. Shaib W., Mahajan R., El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J. Gastrointest Oncol. 2013, 4:308-318.
114. Shi Y.H., Bingle L., Gong L.H., Wang Y.X., Corke K.P., Fang W.G. Basic F.G.F. augments hypoxia-induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007, 39:396-400.
115. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., Gazdar A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97:339-346.
116. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
117. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. GCSF- initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6742-6747.
118. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., Vega-Villegas M.E., Eng C., Steinhauer E.U., Prausova J., Lenz H.J., Borg C., Middleton G., Kröning H., Luppi G., Kisker O., Zubel A., Langer C., Kopit J., Burris H.A. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:2311-2319.
119. Sobrero, A.F., Peeters, M., Price, T.J., Hotko, Y., Cervantes-Ruiperez, A., Ducreux, M., Andre, T., Chan, E., Lordick, F., Tian, Y., Sidhu, R., 2012. Final results of study 20,050,181: a randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second-line treatment (tx) of metastatic colorectal cancer (mCRC), poster 2012 ASCO annual meeting.
120. Sukocheva O., Wang L., Verrier E., Vadas M.A., Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 2009, 150:4484-4492.
121. Taieb J., Tabernero J., Mini E., Subtil F., Folprecht G., Van Laethem J.L., Thaler J., Bridgewater J., Petersen L.N., Blons H., Collette L., Van Cutsem E., Rougier P., Salazar R., Bedenne L., Emile J.F., Laurent-Puig P., Lepage C. PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014, 15:862-873.
122. Thatcher N., Chang A., Parikh P., Rodrigues P., Pereira J., Ciuleanu T., von P., awel J., Thongprasert S., Tan E.H., Pemberton K., Archer V., Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
123. Tol J., Dijkstra J.R., Klomp M., Teerenstra S., Dommerholt M., Vink-Börger M.E., van Cleef P.H., van Krieken J.H., Punt C.J., Nagtegaal I.D. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur. J. Cancer 2010, 46:1997-2009.
124. Troiani T., Zappavigna S., Martinelli E., Addeo S.R., Stiuso P., Ciardiello F., Caraglia M. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Exp. Opin. Biol. Ther. 2013, 13:241-255.
125. Troiani T., Martinelli E., Napolitano S., Morgillo F., Belli G., Cioffi L., Ciardiello F. Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. Curr. Med. Chem. 2014, 21:1639-1653.
126. Troiani T., Napolitano S., Martini G., Martinelli E., Cardone C., Normanno N., Vitagliano D., Morgillo F., Fenizia F., Lambiase M., Formisano L., Bianco R., Ciardiello D., Ciardiello F. Maintenance treatment with cetuximab and BAY869766 increase antitumor efficacy of irinotecan pluscetuximab in human colorectal cancer xenograft models. Clin. Cancer Res. 2015, May 27. pii: clincanres.0211.
127. Van Cutsem E., Rougier P., Köhne C., Stroh C., Schlichting M., Bokemeyer C. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status (abstr 6077). Eur. J. Cancer. Suppl. 2009, 7:345.
128. Van Cutsem E., Köhne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
129. Van Cutsem E., Kohne C., Lang I., Folprecht G., Nowacki M.P., Cascinu S., Shchepotin I., Maurel I., Cunningham D., Tejpar S., Schlichting M., Zubel A., Celik I., Rougier P., Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011, 29:2011-2019.
130. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausová J., Macarulla T., Ruff P., van Hazel G.A., Moiseyenko V., Ferry D., McKendrick J., Polikoff J., Tellier A., Castan R., Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin based regimen. J. Clin. Oncol. 2012, 30:3499-3506.
131. Vasudev N.S., Reynolds A.R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014, 17:471-494.
132. Venook A.P. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005, 103:2435-2446.
133. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
134. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
135. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 1993, 9:138-141.
136. Vogelstein B., Fearon E.R., Kern S.E., Hamilton S.R., Preisinger A.C., Nakamura Y., White R. Allelotype of colorectal carcinomas. Science 1989, 244:207-211.
137. Voutsina A., Tzardi M., Kalikaki A., Zafeiriou Z., Papadimitraki E., Papadakis M., Mavroudis D., Georgoulias V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod. Pathol. 2013, 26:302-313.
138. Wagner A.D., Arnold D., Grothey A.A., Haerting J., Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst. Rev. 2009, CD005392.
139. Wolpin B.M., Clark J.W., Meyerhardt J.A., Earle C.C., Ryan D.P., Enzinger P.C., Zhu A.X., Blaszkowsky L., Battu S., Fuchs C.S. Phase I. study of gefitinib plus FOLFIRI in previously untreated patients with meta- static colorectal cancer. Clin. Colorectal Cancer 2006, 6:208-213.
140. Wu S., Gan Y., Wang X., Liu J., Li M., Tang Y. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis. J. Cancer Res. Clin. Oncol. 2013, 139:891-900.
141. Yonesaka K., Zejnullahu K., Okamoto I., Satoh T., Cappuzzo F., Souglakos J., Ercan D., Rogers A., Roncalli M., Takeda M., Fujisaka Y., Philips J., Shimizu T., Maenishi O., Cho Y., Sun J., Destro A., Taira K., Takeda K., Okabe T., Swanson J., Itoh H., Takada M., Lifshits E., Okuno K., Engelman J.A., Shivdasani R.A., Nishio K., Fukuoka M., Varella-Garcia M., Nakagawa K., Jänne P.A. Activation of ERBB2 signaling causes resistance to the EGFR directed therapeutic antibody cetuximab. Sci. Transl. Med. 2011, 3. 99ra86.
142. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
143. Yunxia Z., Jun C., Guanshan Z., Yachao L., Xueke Z., Jin L. Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. BMC Med. Genet. 2010, 11:34. 34.
144. Zhao Y., Adjei A.A. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 2015, 20:660-673.